

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

09/508828

Confirmation No. 1653

Applicant

Markus Moser et al.

Filed

July 24, 2000

TC/A.U.

1632

Examiner

Anne-Marie Baker

Title

SYNTHETIC POLYPEPTIDE FOR DIAGNOSING AND

TREATING PRION-RELATED DISEASES

Docket No.

SCH-32409

Customer No.

7609

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with Rule 56, applicant is aware of the publications listed in the (Copy enclosed) and in the enclosed copy of Patent Office Form PTO/SB/08A. A copy of each of the publications is enclosed herewith.

Pursuant to 37 C.F.R. 1.97(b) this Statement is being filed after the period set forth in 37 C.F.R. 1.97(b) but before the mailing date of either a final action or a notice of allowance. Enclosed is a check covering the fee set forth in 37 C.F.R. 1.17(p) for consideration of this Statement.

Respectfully submitted,

RANKIN, HILL, PORTER & CLARK LLP

Paul R. Katterle, Reg. No. 36,563

4080 Erie Street Willoughby, Ohio 44094 (216) 566-9700

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below. Box 1450, Alexandria, VA 22313-1450, on the gate indicated below

Signature of Person-Mailing Paper

5/7/2004 Date

Paul R. Katterle Printed Name of Person Mailing Paper 05/12/2004 WARDELR1

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

PRITA TRADEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	09/508828		
Filing Date	7/24/2000		
First Named Inventor	Markus Moser et al.		
Art Unit	1632		
Examiner Name	Robert A. Wax		
Attorney Docket Number	SCH-32409		

			U. S. PATEN	F DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6,537,548	03-25-2003	Prusiner et al.	
		^{US-} 6,451,541	09-17-2002	Winnacker et al.	
		^{US-} 6,372,214	04-16-2002	Prusiner et al.	
		^{US-} 6,290,954	09-18-2001	Prusiner et al.	
		US-			
		US-			
		US-			
	<u> </u>	US-			
		US-			
		US-			
		US-			•
		US-			
	<u> </u>	US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Ĺ.	
						L	
						L	
						L	
						L	
						L	
						Γ	

Examiner Signature	`	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Janese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
Substitute for form 1445/FTO	Application Number	09/508,828			
INFORMATION DISCLOSURE	Filing Date	July 24, 2000			
STATEMENT BY APPLICANT	First Named Inventor	Markus Moser			
<i>(</i> 1)	Art Unit	1653			
(Use as many sheets as necessary)	Examiner Name	Robert A. Wax			
Sheet 2 of 2	Attorney Docket Number	SCH-32409			

	1 211	NON PATENT LITERATURE DOCUMENTS	Γ
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		"Prion (PrPSc)-specific epitope defined by momoclonal antibody", Nature 390: 74-77; 1997 (3 sheets)	
		"New Perspectives in TSE Diagnosis", Prionics AG (1 sheet)	
		"Abstracts of Oak Ridge Posters", Clinical Chemistry 49, No. 10, 2003, pages 1774, 1775	
		"Monoclonal Antibody Against a Peptide of Human Prion", The American Society for Biochemistry and Molecular Biology, Inc. (25 sheets)	
		"A Prion Proten Epitope Selectie for the Pathologically Misfolded Conformation", Nature Medicine, pages 1-7	
		"Binding of Disease-Associated Prion Protein to Plasminogen", Nature, Volume 408, November 23, 2000, pages 479-483	
		"Prion (PrPsc)-Specified Epitope Defined by a Monoclonal Antibody", Nature, Volume 390, November 6, 1997, pages 74-77	
		"Towards a Live Test for Prion Diseases", (1 sheet)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.